The U.S. Food and Drug Administration (FDA) has approved durvalumab in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). The decision marks a significant advancement in bladder cancer treatment and expands the role of immunotherapy in earlier-stage disease management.
The approval allows physicians to use durvalumab alongside standard BCG induction and maintenance therapy for patients diagnosed with high-risk NMIBC. This patient population faces a substantial risk of disease recurrence and progression despite existing treatment options. Therefore, the new approval provides an additional therapeutic strategy for improving long-term outcomes.
According to the FDA, the approval applies to adult patients who have not previously received BCG treatment. The agency stated that durvalumab will be administered in combination with BCG, which has remained a cornerstone therapy for high-risk non-muscle-invasive bladder cancer for decades.
Bladder cancer continues to be one of the most common types of cancer among patients. Non-muscle-invasive bladder cancer makes up a substantial part of new cases of bladder cancer. Although surgery and BCG therapy have historically served as standard treatments, many patients continue to experience recurrence, creating a strong demand for innovative treatment approaches.
The growing burden of bladder cancer continues to highlight the need for innovative treatment options such as durvalumab. The rising global incidence of bladder cancer, particularly among older adults and smokers, remains a major factor driving research and therapeutic development in this area. Additionally, bladder cancer occurs more frequently in men than in women, creating a substantial healthcare challenge worldwide.
According to American Cancer Society estimates for 2026, approximately 84,530 new cases of bladder cancer are expected to be diagnosed in the United States, including about 64,730 cases in men and 19,800 cases in women. Furthermore, an estimated 17,870 deaths from the disease are projected during the year, including approximately 12,640 men and 5,230 women. These statistics underscore the urgent need for more effective therapies that can improve outcomes and reduce disease progression among patients with high-risk bladder cancer.
The FDA’s decision was supported by findings from the Phase 3 POTOMAC clinical trial, which evaluated durvalumab in combination with BCG compared with BCG therapy alone. Researchers designed the study to determine whether adding immunotherapy will increase effectiveness in the management of high-risk NMIBC cases.
The results from the trial showed significant advancements in the disease-free survival of patients on the durvalumab treatment regimen. Consequently, investigators concluded that using immune checkpoint inhibition together with standard BCG treatment would enable them to delay the recurrence of disease and progression.
Durvalumab is an antibody targeting the programmed death-ligand 1 (PD-L1) pathway. It aims at helping the immune system recognize and kill cancer cells more efficiently. Durvalumab has been approved to be used in treating several types of cancer.
The latest approval further contributes to the clinical profile of durvalumab (Imfinzi®). In recent years, the therapy has been approved by regulators for use in several cancers, including lung cancer and other solid tumors. Therefore, the bladder cancer indication extends its footprint in the oncology space.
Industry experts have described the approval as an important milestone because treatment innovation in high-risk NMIBC has progressed slowly over the past several decades. In fact, several reports noted that the durvalumab and BCG combination represents one of the first major therapeutic advancements for this disease setting in more than 30 years.
Moreover, such approval brings into focus the growing trend of the use of immunotherapy in combination with other treatment regimens. Researchers are increasingly considering that the addition of immune checkpoint inhibitors to standard treatments might offer better patient results and longer disease control. Thus, several ongoing studies are still exploring similar strategies in different cancer types.
For patients diagnosed with high-risk NMIBC, preserving bladder function while preventing disease progression remains a primary treatment goal. Thus, therapies that lower recurrence with less aggressive interventions may offer meaningful clinical benefits. Adding durvalumab may help physicians achieve these goals more effectively.
Healthcare providers and oncology specialists are expected to closely monitor real-world outcomes following the introduction of durvalumab into clinical practice. Scientists will further examine the survival rate and durability of the drug once more information becomes available through further research.
The agency stated that full prescribing information on durvalumab for the indication would be provided by official regulatory channels. This approval offers a new ray of hope for those diagnosed with high-risk non-muscle-invasive bladder cancer, emphasizing the continuous evolution of the field of immunotherapy-based cancer treatment modalities. As oncology research continues to advance, durvalumab is expected to play a greater role in expanding treatment options for bladder cancer patients worldwide.
